BHS 002
Alternative Names: BHS-002Latest Information Update: 04 Nov 2020
At a glance
- Originator BioHybrid Solutions; Carnegie Mellon University
- Developer BioHybrid Solutions
- Class Pancreatic enzymes; Protein-drug conjugates; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Exocrine pancreatic insufficiency
Most Recent Events
- 29 Sep 2020 Early research in Exocrine pancreatic insufficiency in USA (unspecified route) (BioHybrid Solutins pipeline, September 2020)
- 01 Mar 2016 BioHybrid Solutions in-licenses NanoArmored™ technology from Carnegie Mellon University (BioHybrid Solutions website, September 2020)